CMOs Of Potent Products Seek Flexible Containment Systems To Increase Safety And Profitability
By Alan E. George, ILC Dover
The interest in the use of containment for the development and manufacture of active pharmaceutical ingredients (APIs), including sensitizers by contract manufacturers and contract research organizations, is expanding. While stating what may be the obvious to those CMOs and CROs who have been handling these types of potent powders, input from a variety of sources are confirming this growing trend.
In the article "Assessing Potent Compound Safety Capabilities at CMOs," SafeBridge notes that the CMO's technical capability to meet clinical or commercial requirements is only one aspect that needs to be evaluated and that there is also a need to ensure, with the same rigor, that these CMOs are capable of safely handling potent APIs and products.